Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alitretinoin oral - Stiefel Laboratories

Drug Profile

Alitretinoin oral - Stiefel Laboratories

Alternative Names: Alitretinoin - Basilea; BAL4079; Cehado; Once-daily oral alitretinoin - Basilea; Toctino

Latest Information Update: 22 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Basilea Pharmaceutica
  • Developer Basilea Pharmaceutica; Stiefel Laboratories
  • Class Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Eczema
  • Discontinued Palmoplantar pustulosis; Systemic lupus erythematosus

Most Recent Events

  • 22 Jan 2019 Launched for Eczema in Slovenia (PO)
  • 21 Jan 2016 Discontinued - Phase-III for Eczema in USA (PO)
  • 23 Nov 2015 Stiefel acquires distribution rights to Alitretinoin in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top